1. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
- Author
-
INZINGER, Martin, WIPPEL-SLUPETZKY, Katharina, WEGER, Wolfgang, RICHTER, Leo, MLYNEK, Alexander, FLEISCHANDERL, Barbara, SCHEURECKER, Christine, SANDOR, Nicolaus, MAIRHOFER, Daniela, SATOR, Paul G., MOSER-OBERTHALER, Sabine, HÄRING, Nina, VIZNEROVA, Petra, PAINSI, Clemens, TANEW, Adrian, PONHOLZER, Peter, TATARSKI, Rafaella, BRENNER, Wilhelm, STINGL, Georg, and SALMHOFER, Wolfgang
- Subjects
PSORIASIS treatment ,DRUG efficacy ,TUMOR necrosis factors ,ADALIMUMAB ,INFLIXIMAB ,ETANERCEPT - Abstract
This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p = 2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF